Thrombocythemia, Essential research hub
26 indexed studies · 10 currently recruiting
- recruitingPHASE3
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
This study is for people already taking a medicine called bomedemstat for certain blood cancers like thrombocythemia or myelofibrosis. It aims to gather more information over a longer time about how safe and effective bomedemstat is for those who are already benefiting from it.
United States · Australia · Hong Kong - active not recruitingPHASE3
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
This study is testing a new medication called imetelstat for people with myelofibrosis, a rare bone marrow cancer, who haven't responded well to previous treatments. It compares imetelstat to other available therapies to see if it improves how long people live.
United States · Argentina · Australia - active not recruitingPHASE1
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
This study is testing a new medicine, IOA-244, for people with certain advanced cancers, including lymphoma and melanoma. It aims to see if the medicine is safe and if it can help the body's immune system fight cancer, both alone and with other treatments.
Italy · United Kingdom - recruitingPHASE3
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
This study looks at a new drug, elritercept, for people with myelofibrosis and anaemia who are already taking ruxolitinib. It compares elritercept to a dummy drug (placebo) to see if it improves anaemia and other symptoms, and how safe it is.
United States · Argentina · Australia - active not recruitingPHASE1
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
This study looks at a new drug, INCB057643, for people with certain blood cancers like myelofibrosis. It checks if the drug is safe, what dose works best, and if it helps by itself or when given with another medicine called ruxolitinib.
United States · Canada · China - recruitingPHASE2
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis
This study looks at a new medicine called Elritercept for myelofibrosis, a bone marrow condition. Researchers want to see if it's safe and effective when used alone or with another medicine called Ruxolitinib. They're also checking how it affects symptoms and red blood cell counts.
Australia · Brazil · France - active not recruitingPHASE3
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
This study is looking at a new combination treatment for myelofibrosis, a blood disorder. It combines a drug called Selinexor with Ruxolitinib to see if it's safe and helps people who haven't tried other similar treatments for myelofibrosis before.
United States · Australia · Belgium - active not recruitingPHASE3
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
This study is testing a new medicine called pelabresib alongside an existing treatment (ruxolitinib) for adults with myelofibrosis who haven't tried similar drugs before. It aims to see if this combination works better than ruxolitinib alone to help manage symptoms and spleen size.
United States · Australia · Austria - active not recruitingPHASE1, PHASE2
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
This study looks at a new drug, BMS-986158, alone or with other medicines like Ruxolitinib or Fedratinib, for a type of blood cancer called myelofibrosis. Researchers want to see if these treatments are safe and how well they work.
United States · Australia · France - recruiting
Clinical Epidemiology in Contemporary Patients With Myelofibrosis.
This study is looking at people living with myelofibrosis, a rare bone marrow condition, across Europe. We're gathering information on how the disease affects them and how it's treated in real life. This helps us understand the condition better and improve care for future patients.
Armenia · Denmark · France - active not recruitingPHASE2
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
This study looks at a new drug, selinexor, for people with myelofibrosis whose current treatment hasn't worked well enough. It compares selinexor to standard care chosen by doctors to see if it's safe and effective.
United States · China · France - ongoing, recruitingTherapeutic exploratory (Phase II)
INCB 39110-801 A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (INCB039110)
This study offers ongoing treatment with a medicine called Itacitinib for adults who have already participated in earlier studies of this drug. It primarily monitors for any side effects and ensures continued access to the medication for conditions like myelofibrosis or chronic graft-versus-host disease.
Italy · Spain · Austria - recruitingPHASE3
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
This study looks at adding a new medicine, navtemadlin, to an existing treatment, ruxolitinib, for people with myelofibrosis. It aims to see if this combination works better for those whose myelofibrosis isn't fully controlled by ruxolitinib alone.
United States · Australia · Austria - active not recruitingPHASE2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis
This study is testing a new medicine called GB2064 for people with myelofibrosis, a rare blood cancer. It will check if the medicine is safe, how the body handles it, and if it has any effects on the disease over nine months.
United States · Australia · Germany - recruitingPHASE1, PHASE2
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
This study is looking into a new drug, TL-895, for myelofibrosis, a bone marrow disorder. It’s for people who haven't tried a common treatment called ruxolitinib yet, or those who aren't getting enough benefit from ruxolitinib alone.
United States · France · Germany - recruiting
Research Platform Myelofibrosis and Anemia
This study in Germany looks at how people with myelofibrosis and anaemia are treated in real life. It collects information about their health, treatments, and how they feel over time to understand common treatment patterns and changes in their care.
Germany - active not recruitingPHASE2
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
This study is for people already taking the drug itacitinib in other Incyte studies. It allows them to continue getting the treatment if it's helping and they are tolerating it well. It's for conditions like myelofibrosis, lung transplant problems, and chronic graft-versus-host disease.
United States · Austria · Belgium - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis (REFINE)
This study looks at a new medicine, Navitoclax, for people with a blood condition called myelofibrosis. Researchers want to see if it can shrink an enlarged spleen and improve symptoms, either on its own or with another medicine called Ruxolitinib.
Spain · Italy · Greece - authorisedTherapeutic exploratory (Phase II)
A Phase 2 Open-Label Study to Evaluate Momelotinib in combination with Luspatercept in Participants with Transfusion Dependent Primary or Secondary Myelofibrosis
This study looks at a new drug combination, Momelotinib and Luspatercept (Reblozyl), for people in the UK with myelofibrosis who need regular blood transfusions. The main goal is to see if these medicines can help people stop needing transfusions for at least 12 weeks.
France · Italy · Germany - authorisedTherapeutic exploratory (Phase II)
RuxoTam; A phase II study to evaluate safety and efficacy of tamoxifen in combination with Ruxolitinib in patients with myelofibrosis
This study is looking at a new way to treat myelofibrosis, a rare blood condition. It combines a drug called tamoxifen with another drug called ruxolitinib. Researchers want to see if this combination is safe and works better than current treatments. It's for adults with myelofibrosis.
Netherlands - authorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive
This study is looking into a new treatment for myelofibrosis, a rare bone marrow condition. It compares a new drug called pelabresib, given with an existing medicine (ruxolitinib), against ruxolitinib alone. The aim is to see if the new combination can shrink the spleen and improve symptoms.
Belgium · Germany · Austria - recruitingPHASE1, PHASE2
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
This study is testing a new medicine, nuvisertib, for myelofibrosis. It aims to see if it's safe and how it works, either alone or with ruxolitinib. It's for people whose current treatments aren’t working well.
United States · Australia · Belgium - recruitingPHASE2
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
This study looks at a new drug, selinexor, for people with a bone marrow condition called myelofibrosis. It's for those who haven't tried certain other treatments and have low to normal platelet counts. The main aim is to see if selinexor can shrink an enlarged spleen.
United States · Belgium · Bulgaria - recruitingPHASE2
Methods of T Cell Depletion Trial (MoTD)
This study compares different ways to prevent a complication called GvHD after stem cell transplants for various blood cancers. It's looking for the best treatment plan to help patients recover well, using common medicines like Thymoglobulin, Cyclophosphamide, Cyclosporine, Sirolimus, and Mycophenolate Mofetil.
United Kingdom - active not recruitingPHASE3
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
This study looks at a new drug, Luspatercept, for people with myelofibrosis and anaemia who need regular blood transfusions and are already taking a JAK2 inhibitor. We want to see if it helps reduce the need for transfusions.
United States · Argentina · Australia - not yet recruitingPhase II
A study testing two targeted medicines, bomedemstat, which helps normalise blood cell development, and momelotinib, which reduces symptoms and anaemia, to see whether the combination is safe and effective for people with myelofibrosis
This study looks at combining two medicines, bomedemstat and momelotinib, for people with myelofibrosis. It aims to see if this combination is safe and helps more than momelotinib alone, especially for those whose first treatment isn't working well.
United Kingdom · England · France